{"description":"Safety population included all participants who received at least one dose of protocol specified treatment and were in remission at the time of transplant.","eventGroups":[{"description":"Myeloablative (bone marrow depletion) conditioning protocol as per standard of care at the investigator's discretion followed by granulocyte colony-stimulating factor (GCSF)-mobilized human leukocyte antigen (HLA)-matched, related or unrelated donor allogeneic peripheral blood stem cells (unmanipulated), standard graft-versus-host disease (GVHD) prophylaxis as per standard of care at the investigator's discretion and rasburicase 0.20 mg/kg/day administered by intravenous infusion for 5 consecutive days. If after 5 days of rasburicase the participant's uric acid plasma level remains above 5 mg/dL, rasburicase may be continued for up to 7 days in total.","id":"EG000","otherNumAffected":21,"otherNumAtRisk":21,"seriousNumAffected":10,"seriousNumAtRisk":21,"title":"Rasburicase Group"},{"description":"Historical chart review of patients from the Blood and Marrow Transplant database who received myeloablative allogeneic stem cell/bone marrow transplantation followed by standard GVHD prophylaxis in the past 10 years. Participants received allopurinol per institutional guidelines.","id":"EG001","otherNumAffected":21,"otherNumAtRisk":21,"seriousNumAffected":9,"seriousNumAtRisk":21,"title":"Control Group"}],"frequencyThreshold":"4","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":21},{"groupId":"EG001","numAffected":11,"numAtRisk":21}],"term":"Vomiting"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":21},{"groupId":"EG001","numAffected":9,"numAtRisk":21}],"term":"Fever"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":21},{"groupId":"EG001","numAffected":19,"numAtRisk":21}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":21},{"groupId":"EG001","numAffected":9,"numAtRisk":21}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":21},{"groupId":"EG001","numAffected":17,"numAtRisk":21}],"term":"Mucositis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":2,"numAtRisk":21}],"term":"Rash"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":21},{"groupId":"EG001","numAffected":2,"numAtRisk":21}],"term":"Edema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Tongue numbness"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Thrombocytopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Hemolytic anemia"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Seizure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Hypoxia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Engraftment syndrome"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Venoocclusive disease"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death","organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":21},{"groupId":"EG001","numAffected":7,"numAtRisk":21}],"term":"Relapsed disease"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":21},{"groupId":"EG001","numAffected":1,"numAtRisk":21}],"term":"Infection from aGVHD flare"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":21},{"groupId":"EG001","numAffected":1,"numAtRisk":21}],"term":"Respiratory failure"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"H1N1 influenza"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Resulted in death","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":21},{"groupId":"EG001","numAffected":0,"numAtRisk":21}],"term":"Metapneumovirus"}],"timeFrame":"Up to 71 months"}